# Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

> **NCT04526665** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Ipsen** · enrollment: 161 (actual)

## Conditions studied

- Primary Biliary Cirrhosis

## Interventions

- **DRUG:** Elafibranor 80mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04526665
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-24
- **Primary completion:** 2023-06-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04526665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04526665, "Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04526665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*